Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on March 4, 2026. The filing was submitted on March 5, 2026. The transaction was executed by BNP Paribas SA as part of GSK's existing share buyback programme, pursuant to a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 550,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,109.00 GBp; highest price paid was 2,149.00 GBp.
- Average Price: Volume-weighted average price paid was 2,129.91 GBp.
- Programme Progress: Since February 17, 2026, the Company has purchased a total of 5,816,000 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 245,707,094 ordinary shares in treasury.
- Shares in Issue: 4,070,455,394 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.04% of the total voting rights.
The filing text does not provide values for revenue, profit, cash flow, margins, or debt.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares due to the buyback activity. The total number of voting rights remains 4,070,455,394, which serves as the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q4 Results for 2025. No new specific guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 17, 2026 (stated as 5,816,000).
- Confirm the updated treasury share count of 245,707,094 and the resulting 6.04% voting rights attribution.
- Review the detailed schedule of purchases across trading venues (BATE, CHIX, XLON) to confirm execution prices and volumes.
- Consult the referenced 2024 Form 20-F and 2025 Q4 Results for detailed risk factors and broader financial context not included in this transaction report.